Mark Niosi

1.4k citations
23 papers · 578 · h-index 13

Impact in

  • Pharmacology top 2%
    • Pharmacogenetics and Drug Metabolism
    • Drug-Induced Hepatotoxicity and Protection
  • Physiology top 10%
    • Adenosine and Purinergic Signaling

Papers in

  • Oncology 14
    • Drug Transport and Resistance Mechanisms 13
  • Pharmacology 13
    • Pharmacogenetics and Drug Metabolism 12
Co-authors
Jian Lin (8 shared papers)Li Di (7 shared papers)Keith Riccardi (6 shared papers)Manthena V. S. Varma (3 shared papers)Theunis C. Goosen (5 shared papers)Rachel E. Kosa (3 shared papers)Phillip D. Yates (1 shared paper)Cheng Chang (1 shared paper)
Journals
Drug Metabolism and Disposition (13 papers)Drug Metabolism and Pharmacokinetics (1 paper)Bioorganic & Medicinal Chemistry (1 paper)Xenobiotica (1 paper)Journal of Pharmacology and Experimental Therapeutics (1 paper)
Partner nations
United StatesUnited KingdomChina

In The Last Decade

Mark Niosi

22 papers receiving 567 citations

Peers

Mark Niosi
Comparison fields: 5 of 84
  • Pharmacology 218
  • Physiology 49
  • Oncology 261
  • Pediatrics, Perinatology and Child Health 95
  • Clinical Biochemistry 28
Replace Masamitsu Maekawa with:
Masamitsu Maekawa Japan
Ingelore Hackbarth Germany
Atsushi Ose Japan
William Neway United States
Stella Vincent United States
Xiao-Hui Guo China
Christine Wegler Sweden
Bahman M. Sadeghpour Italy
Kazutomi Kusano Japan
Wataru Kishimoto Japan
Mark Niosi relative to Masamitsu Maekawa Japan Masamitsu Maekawa's profile →
Citations per field
00.5×2×2.7×
Masamitsu Maekawa · 1×
Citations per year

Countries citing papers authored by Mark Niosi

Since Specialization
Citations

This map shows the geographic impact of Mark Niosi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Niosi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Niosi more than expected).

Fields of papers citing papers by Mark Niosi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Niosi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Niosi. The network helps show where Mark Niosi may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Niosi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Niosi Line = papers co-authored together Mark Niosi links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Plasma Protein Binding of Challenging Compounds
Journal of Pharmaceutical Sciences ·Keith Riccardi, Shannon Cawley, Phillip D. Yates, Cheng Chang, Carrie Funk, Mark Niosi, Jian Lin, Li Di
201591
2
A-317491, a selective P2X3/P2X2/3 receptor antagonist, reverses inflammatory mechanical hyperalgesia through action at peripheral receptors in rats
European Journal of Pharmacology ·Gang Wu, Garth T. Whiteside, Gary Lee, Scott Nolan, Mark Niosi, Michelle Pearson, Victor I. Ilyin
200467
3
Utility of the carboxylesterase inhibitorbis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor
Xenobiotica ·Heather Eng, Mark Niosi, Thomas S. McDonald, Angela Wolford, Y. Chen, S. T. M. Simila, Jonathan Bauman, Joseph S. Warmus, Amit S. Kalgutkar
201054
4
Organic Anion Transporter 2–Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability–Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs
Journal of Pharmacology and Experimental Therapeutics ·Emi Kimoto, Sumathy Mathialagan, Laurie Tylaska, Mark Niosi, Jian Lin, Anthony Carlo, David A. Tess, Manthena V. S. Varma
201848
5
Novel Method to Predict In Vivo Liver-to-Plasma Kpuu for OATP Substrates Using Suspension Hepatocytes
Drug Metabolism and Disposition ·Keith Riccardi, Jian Lin, Zhenhong Li, Mark Niosi, Sangwoo Ryu, Wenyi Hua, Karen Atkinson, Rachel E. Kosa, John Litchfield, Li Di
201744
6
Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro–In Vivo Scaling of Hepatic Uptake Clearance
Drug Metabolism and Disposition ·Tom De Bruyn, Ayşe Ufuk, Carina Cantrill, Rachel E. Kosa, Yi-An Bi, Mark Niosi, Sweta Modi, A. David Rodrigues, Larry M. Tremaine, Manthena V. S. Varma, Aleksandra Galetin, J. Brian Houston
201843
7
Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides
Drug Metabolism and Disposition ·Rhishikesh Thakare, Hongying Gao, Rachel E. Kosa, Yi-An Bi, Manthena V. S. Varma, Matthew A. Cerny, Raman Sharma, Max Kühn, Bingshou Huang, Yiping Liu, Aijia Yu, Gregory S. Walker, Mark Niosi, Larry M. Tremaine, Yazen Alnouti, A. David Rodrigues
201741
8
Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity
Drug Metabolism and Disposition ·Brahim Achour, Alyssa Dantonio, Mark Niosi, Jonathan J. Novak, John K. Fallon, Jill Barber, Philip C. Smith, Amin Rostami‐Hodjegan, Theunis C. Goosen
201737
9
Determination of Unbound Partition Coefficient and in Vitro–in Vivo Extrapolation for SLC13A Transporter–Mediated Uptake
Drug Metabolism and Disposition ·Keith Riccardi, Zhongrui Li, Janice A. Brown, Matthew Gorgoglione, Mark Niosi, J Gosset, Kim Huard, Derek M. Erion, Li Di
201626
10
Data Generated by Quantitative Liquid Chromatography-Mass Spectrometry Proteomics Are Only the Start and Not the Endpoint: Optimization of Quantitative Concatemer-Based Measurement of Hepatic Uridine-5′-Diphosphate–Glucuronosyltransferase Enzymes with Reference to Catalytic Activity
Drug Metabolism and Disposition ·Brahim Achour, Alyssa Dantonio, Mark Niosi, Jonathan J. Novak, Zubida M. Al‐Majdoub, Theunis C. Goosen, Amin Rostami‐Hodjegan, Jill Barber
201822
11
In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes
Drug Metabolism and Disposition ·Kimberly Lapham, Ernesto Callegari, Julie Cianfrogna, Jian Lin, Mark Niosi, Christine C. Orozco, Raman Sharma, Theunis C. Goosen
202020
12
A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects
Drug Metabolism and Disposition ·Rui Li, Mark Niosi, Nathaniel Johnson, David A. Tess, Emi Kimoto, Jian Lin, Xin Yang, Keith Riccardi, Sangwoo Ryu, Ayman El‐Kattan, Tristan S. Maurer, Larry M. Tremaine, Li Di
201818
13
Defining the key pharmacophore elements of PF-04620110: Discovery of a potent, orally-active, neutral DGAT-1 inhibitor
Bioorganic & Medicinal Chemistry ·Robert L. Dow, Melissa P. Andrews, Jiancheng Li, E. Michael Gibbs, Angel Guzmán-Pérez, Jennifer L. LaPerle, Qifang Li, Dawn Mather, Michael J. Munchhof, Mark Niosi, Leena Patel, Christian Perreault, Susan Tapley, William J. Zavadoski
201318
14
2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety
Journal of Medicinal Chemistry ·Robert L. Dow, Mark Ammirati, Scott W. Bagley, Samit K. Bhattacharya, Leonard Buckbinder, Christian Cortés‐Campos, Ayman El‐Kattan, Kristen K. Ford, Gary B. Freeman, Cristiano R. W. Guimarães, Shenping Liu, Mark Niosi, Athanasia Skoura, David A. Tess
201811
15
A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 2: Prospectively Predicting Systemic and Liver Exposure in Healthy Subjects
Drug Metabolism and Disposition ·Rui Li, Emi Kimoto, Mark Niosi, David A. Tess, Jian Lin, Larry M. Tremaine, Li Di
20188
16
Novel in vitro method to predict in vivo liver-to-plasma unbound partition coefficient
Drug Metabolism and Pharmacokinetics ·Li Di, Keith Riccardi, Zhenhong Li, Jian Lin, Sangwoo Ryu, Mark Niosi
20187
17
6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1H-Indole-3-Carboxylic Acid is a Highly Selective Substrate for Glucuronidation by UGT1A1, Relative to β-Estradiol
Drug Metabolism and Disposition ·Kimberly Lapham, Jian Lin, Jonathan J. Novak, Christine C. Orozco, Mark Niosi, Li Di, Theunis C. Goosen, Sangwoo Ryu, Keith Riccardi, Heather Eng, Kimberly O. Cameron, Amit S. Kalgutkar
20185
18
A Sensitive Method for the Quantitation of the Peptide-Based Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Plasma Using Microfluidics Chromatography Tandem MS
Bioanalysis ·Amanda King‐Ahmad, Amit S. Kalgutkar, Mark Niosi, Heather Eng, Christopher L. Holliman
20185
19
The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite
Drug Metabolism and Disposition ·Martin E. Dowty, Ruolun Qiu, Alyssa Dantonio, Mark Niosi, Angela C. Doran, Amanda Balesano, Stephen W. Wright, Gregory S. Walker, Raman Sharma
20244
20
Clotrimazole Identified as a Selective UGT2B4 Inhibitor Using Canagliflozin-2′-O-Glucuronide Formation as a Selective UGT2B4 Probe Reaction
Drug Metabolism and Disposition ·Kimberly Lapham, Nicholas Ferguson, Mark Niosi, Theunis C. Goosen
20244

About Mark Niosi

Mark Niosi is a scholar working on Oncology, Pharmacology, Molecular Biology, Pediatrics, Perinatology and Child Health and Organic Chemistry, having authored 23 papers that have together received 578 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (13 papers), Pharmacogenetics and Drug Metabolism (12 papers), Pharmacological Effects and Toxicity Studies (5 papers), Metabolism, Diabetes, and Cancer (2 papers), Receptor Mechanisms and Signaling (2 papers), Cancer therapeutics and mechanisms (2 papers), Biochemical and Molecular Research (2 papers) and Click Chemistry and Applications (1 paper). The work is most often cited by research in Pharmacology (218 citations), Physiology (49 citations), Oncology (261 citations), Pediatrics, Perinatology and Child Health (95 citations) and Clinical Biochemistry (28 citations). Mark Niosi has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Jian Lin, Li Di, Keith Riccardi, Manthena V. S. Varma, Theunis C. Goosen, Rachel E. Kosa, Phillip D. Yates, Cheng Chang, Victor I. Ilyin and Scott Nolan. Their work appears in journals such as Drug Metabolism and Disposition, Drug Metabolism and Pharmacokinetics, Bioorganic & Medicinal Chemistry, Xenobiotica and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masamitsu MaekawaBreakdown of academic impact, for papers by Ingelore HackbarthBreakdown of academic impact, for papers by Atsushi OseBreakdown of academic impact, for papers by William NewayBreakdown of academic impact, for papers by Stella VincentBreakdown of academic impact, for papers by Xiao-Hui GuoBreakdown of academic impact, for papers by Christine WeglerBreakdown of academic impact, for papers by Bahman M. SadeghpourBreakdown of academic impact, for papers by Kazutomi KusanoBreakdown of academic impact, for papers by Wataru Kishimoto